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Brief Summary: We examined HCV-infected patients born in Africa but resident in the UK for 
treatment outcomes for DAA therapy. The unusual HCV subtypes identified in many patients 




MRC-University of Glasgow Centre for Virus Research 
Sir Michael Stoker Building 
Garscube Campus 
464 Bearsden Road 
Glasgow G61 1QH 
UK 
Tel: +44 (0)141 330 4028 
Fax: +44 (0)141 330 3520 
E-mail: john.mclauchlan@glasgow.ac.uk 
 
Request for Reprints: John McLauchlan, MRC-University of Glasgow Centre for Virus Research, Sir 
Michael Stoker Building, Garscube Campus, 464 Bearsden Road, Glasgow G61 1QH, UK 






















Background Chronic HCV infection affects 71 million individuals, mostly residing in low- and middle-
income countries (LMICs). Direct-acting antivirals (DAA) give high rates of sustained virological 
response (SVR) in high income countries where a restricted range of HCV genotypes/subtypes 
circulate.  
Approach We studied UK-resident patients born in Africa to examine DAA effectiveness in LMICs 
where there is far greater breadth of HCV genotypes/subtypes. Viral genome sequences were 
determined from 233 patients. 
Results Full-length viral genomic sequences for 26 known subtypes and 5 previously unidentified 
isolates covering 5 HCV genotypes were determined. From 149 patients who received DAA 
treatment/retreatment, the overall SVR was 93%. Treatment failure was associated primarily with 
two subtypes, gt1l and gt4r, using Sofosbuvir/Ledipasvir. These subtypes contain natural resistance-
associated variants that likely contribute to poor efficacy with this drug combination. Treatment 
failure was also significantly associated with hepatocellular carcinoma.  
Conclusions DAA combinations give high SVR rates despite the high HCV diversity across the African 
continent except for subtypes gt1l and gt4r, which respond poorly to Sofosbuvir/Ledipasvir. These 
subtypes are widely distributed across Western, Central and Eastern Africa. Thus, in circumstances 
where accurate genotyping is absent, Ledipasvir and its generic compounds should not be 
considered as a recommended treatment option.  
 





















Direct-acting antivirals (DAA) capable of clearing chronic HCV infection from >90-95% of treated individuals 
are a cornerstone of the WHO strategy to eliminate viral hepatitis as a public health concern by 2030 [1]. 
Consequently, many high-income countries (HICs) have implemented action plans for controlling infection 
and transmission to achieve HCV eradication. By contrast, low- and middle-income countries (LMICs) face 
obstacles and challenges limiting their ability to implement similar strategies [2]. Moreover, clinical trials and 
data on DAA efficacy are almost exclusively derived from studies in HICs where circulating HCV 
genotypes/subtypes are more restricted than those in LMICs [3-6]. In particular, most subtypes of HCV 
genotypes 4, 5 and 6 have been largely neglected, yet they represent about 15% of chronic HCV infections 
[7]. 
We recently reported a substantial gap in our knowledge of HCV genomic sequences circulating in LMICs 
across large geographic areas [8]. In addition, we and others have identified HCV genotype(gt)1 and gt4 
subtypes in infected patients of African origin that do not respond to DAA therapy as well as subtypes 
typically transmitted in HICs; treatment failure using a Sofosbuvir/Ledipasvir (SOF/LDV) combination has 
been particularly evident with HCV subtypes gt1l [9, 10] and gt4r [10-14]. Reduced DAA efficacy for these 
subtypes is frequently related to polymorphisms in DAA target proteins (herein defined as resistance-
associated variants [RAV]), which can give inherent resistance to certain DAA combinations. 
In this study, we address the issue of treatment outcomes in response to DAA therapy in HCV-infected 
individuals originating from Africa but residing in the UK. We also aimed to increase the number of available 






















Study Design and Patients 
HCV-infected patients were enrolled into the HCV Research UK cohort at clinical sites in the UK [15]. All 
patients whose country of birth was in Africa were included in this study. Further details of the HCV Research 
UK clinical database are given in Supplementary Methods. The study conforms to the ethical guidelines of 
the 1975 Declaration of Helsinki as reflected in a priori approval by the institution’s human research 
committee. Ethics approval for HCV Research UK was given by NRES Committee East Midlands - Derby 1 
(Research Ethics Committee reference 11/EM/0314). 
Next Generation Sequencing (NGS) by Metagenomics and Target Enrichment 
The NGS methods for determining HCV viral sequences by metagenomics and target enrichment have been 
published previously [16], and are described in Supplementary Methods. 
HCV Sequence and Variant Analysis 
NGS data quality was assessed using FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) 
and low-quality bases (Phred score <30 or read length <50 nucleotides) were trimmed using Trim Galore! 
script (https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). Cleaned reads were submitted 
for de novo assembly using SPAdes [17]. Where de novo assembly failed to generate a full-length contig, 
reads were mapped to the closest reference genome. Reference genomes were selected by a kmer-based 
approach using unique kmers from all HCV genotypes. Reads were mapped to the reference genome (or 
to de novo contigs) using Tanoti read mapper (https://bioinformatics.cvr.ac.uk/software/tanoti/). Any minor 
variants associated with DAA resistance were identified using the GLUE software package samReporter with 





















Statistical analyses were performed using STATA v10. Continuous variables were reported as median (and 
interquartile range) and analysed by the Mann Whitney U test for univariate analysis. Categorical univariate 
analysis was performed using Fishers exact test. Multivariate analysis was carried out using logistic 
regression. Variables with a p-value of <0.1 in univariate analysis were included in multivariate analysis. 
RESULTS 
Demographics of Subjects Originating from Africa in the Cohort 
Within the HCV Research UK cohort [15], 319 patients were born in 32 countries across Africa. Analysis of 
this African group revealed that 66.5% were male (Table 1) with an age range of 24-88 years, averaging 59 
years. The most frequently cited probable sources of infection were ‘Born Abroad’ (40%) and ‘Blood/Blood 
Products’ (17%; Table 1). ‘Born Abroad’ was included as it was significantly associated as a risk factor for 
infection in a previous study [20]. Only 10% of individuals probably acquired infection through injecting drug 
use, considerably lower than that for white UK nationals from the HCV Research UK cohort (n=5360/8419; 
64%). Moreover, 44 cases were cited as ‘Other’ (14% of the cohort) as a probable source of infection; within 
this category, there was a range of possible sources of infection but none were reported as having acquired 
infection in the UK (Supplementary Table 1). Indeed for 11 individuals, country of birth was recorded 
specifically as the likely location for acquiring infection (Table 1 and Supplementary Table 1).  
A high proportion of the African cohort had cirrhosis (41%; n=131) and within this group, decompensated 
disease was found in 42 individuals (32%). In addition, 25 cases (19%) were diagnosed with hepatocellular 
carcinoma (HCC; Table 1). The percentage of UK-born individuals of white ethnicity in the HCV Research UK 
database with cirrhosis was 37% (n=3141/8419). Within this group, the percentage with more severe liver 
disease was considerably less (38%; n=1203/3141; Supplementary Table 2) compared to the African group 



















Identification of HCV Genotypes and Subtypes by Unbiased NGS and Target Enrichment 
Using a NGS target enrichment approach (described in Supplementary Methods) [16], we generated 
sequence data covering the entire HCV coding region for samples from 233 individuals (Supplementary Table 
3); viral sequence data were determined from another 14 samples collected from patients after undergoing 
unsuccessful DAA therapy. Samples that did not yield viral sequence data were mostly obtained either 
during or after antiviral therapy (64/86 [75%]) at which point either very low or undetectable viral loads 
would be evident in circulating blood.  
Using maximum likelihood phylogenetic analysis we detected seven gt1 subtypes (and four gt1 unassigned 
isolates), three gt2 subtypes (and one gt2 unassigned isolate), two gt3 subtypes, 13 gt4 subtypes and two 
gt5a sequences; unassigned isolates differed from classified HCV subtypes by at least 15% at the nucleotide 
level [21]. Compared to publicly available data, our analysis considerably increases the genomic information 
for 8 subtypes (gt1g, gt1l, gt3h, gt4a, gt4c, gt4k, gt4n and gt4r). The distribution and occurrence of the HCV 
genotypes and subtypes identified in each individual and their country of origin is shown in Fig. 1 and 
Supplementary Tables 3 and 4. From analysis of the geographical locations of all confirmed subtypes for HCV 
genotypes 1-4 available in the publish d literature [21-25], there were only 7 subtypes previously found in 
Africa that were absent in our sequencing dataset (Supplementary Table 4).   
The most highly represented countries in each geographic African region for sequence data were Egypt 
(n=62; Northern Africa), Nigeria (n=31; Western Africa), DRC/Republic of Congo (n=20; Central Africa), 
Somalia (n=29; Eastern Africa) and South Africa (n=9; Southern Africa) (Fig. 1A and B). HCV subtypes gt1a and 
gt1b were ubiquitous in patients born across Africa with either subtype found in individuals from 18/27 
countries (67%). Genotype 4a was the most common subtype in Egyptian individuals, as previously reported 
[26, 27]. Aside from gt1a, gt1b and gt4a, the most frequently detected subtypes were gt3a and gt4r, which 
were found in individuals from 9/27 and 7/27 countries respectively. Gt4r was present in patients originating 



















(Burundi, Eritrea, Ethiopia and Somalia) (Fig. 1A and B). Strikingly, 38% (11/29) of sequences from Somalian 
patients were gt4r (Fig. 1B). Therefore, gt4r is likely to be distributed across large areas of Africa and, 
assuming that most individuals were infected in their originating country, may dominate in certain countries. 
Gt3h was also detected in patients from Somalia and Zimbabwe and hence may be the most common gt3 
subtype circulating in certain African countries. Indeed, gt3h was the second most prevalent subtype in 
Somalian individuals after gt4r. In addition, our sequence studies identified 5 unassigned strains for gt1 and 
gt2, which were detected in patients from Nigeria (n=3), Cameroon (n=1) and Ghana (n=1) (Supplementary 
Table 3).  
We compared the genotype/subtypes identified by NGS analysis with those recorded by the clinical site who 
employed commercial kits (such as the INNO-LiPa test). We obtained genotype and subtype data for both 
commercial assays and NGS for 133 and 60 samples respectively (genotype and subtype). HCV genotype was 
identical in 124 samples (93%) but the percentage of concordant HCV subtypes was much lower (n=41 out of 
60 samples [68%]). The majority of mismatches corresponded to subtypes that are not typically identified or 
differentiated in commercial kits (data not shown).  
Outcomes of DAA Therapy  
We evaluated treatment outcomes for all DAA drug combinations used to treat the cohort, yielding data on 
149 patients. This group included 12 patients who had received prior DAA therapy on one (n=11 patients) or 
two (n=1 patient) occasions. Hence, there was a total of 162 treatment episodes recorded (Table 2). Two 
patients were lost to follow-up or died before treatment outcome was known but were included in the 
overall analysis. 
From univariate analysis, presence of HCC (p=0.006) was significantly associated with DAA failure; a higher 
failure rate was noted also for those with decompensated liver disease (p=0.061; Supplementary Table 5). 
No other demographic or clinical characteristics, including HIV infection, were associated with failed 



















patients were significantly more likely to respond compared to treatment-experienced individuals 
(Supplementary Table 5). Stratifying the various treatment regimens according to either IFN or DAA targeted 
at HCV proteins (NS3, NS5A and NS5B) revealed that prior exposure to antivirals against NS5A and NS5B was 
significantly associated with subsequent treatment failure (Supplementary Table 5). 
To identify the basis of this finding, we examined the viral sequence data for the group that received DAA 
therapy. In total, viral sequences were available for 131 patients who had received 144 treatment episodes. 
The most striking observation from analysing the different DAA combinations for these patients was low SVR 
rates for gt1l and gt4r with NS5A/NS5B antiviral combinations (0% and 44% respectively; Table 3). Statistical 
analysis of both HCV subtypes combined showed that a low SVR was highly significant in both univariate and 
multivariate analysis compared to other subtypes (Supplementary Table 5). By comparison, high SVR rates 
were achieved for other subtypes that are common across Africa but found far less frequently in HCV-
infected populations in other continents.  
Virological Characteristics of Responder-Relapsers/Non-Responders to DAA-based Therapy and 
Retreatment Outcomes 
In terms of virological outcomes (i.e. excluding patients either lost to follow up or who died before outcome 
was known), there were 24 treatment episodes with DAA that led to treatment failure (Table 2) in 19 
patients. Final records for these patients showed that 9 were successfully retreated. 4 patients who were 
retreated did not achieve SVR and therefore, 10 patients remained viremic (Table 4). 5 patients were 
retreated with the same drug combination and only 2 (both infected with gt3a) achieved SVR. The other 3 
patients were infected with either gt1l (n=2) or gt4r (n=1). 6 out of 7 patients who received retreatment with 
more potent DAA combinations, either GLE/PIB (GLE, Glecaprevir; PIB, Pibrentasvir) or SOF/VEL/VOX (VEL, 
Velpatasvir; VOX, Voxilaprevir), achieved SVR; the one retreatment failure in this category was infected with 




















Sequences in NS5A for Subtypes gt1l and gt4r Potentially Associated with Lower Response to DAA Therapy 
Given the frequency of gt1l and gt4r treatment failure, we examined all individuals in the cohort infected 
with these HCV subtypes for both their viral sequences and outcomes from anti-viral therapy. Sseven 
patients were infected with gt1l (Supplementary Table 4), six of whom received DAA therapy (Table 5). 26 
patients were infected with gt4r (Supplementary Table 4), 12 of whom received at least one episode of DAA 
therapy (Table 5). Combining the data for gt1l and gt4r indicated that there were 13 instances of DAA 
treatment failure, 10 of which resulted from SOF/LDV treatment; the remaining treatment failures arose 
from use of SOF/DCV (DCV; Daclatasvir; n=2) for a gt1l-infected individual and SOF/VEL/VOX for retreatment 
in a gt4r infection (Table 4). Previously, we have shown sequences from these subtypes can share a common 
motif in NS5A, M28R30M31, that could give resistance to NS5A inhibitors and thereby reduce effectiveness of 
DAA therapy [10]. From examining the NS5A coding region for all gt1l and gt4r viral sequences in the cohort, 
we found that gt1l had two patterns at positions 28, 30 and 31; methionine was invariant at positions 28 and 
31 while position 30 encoded either arginine or glutamine (Table 5). The same positions in gt4r had more 
complex amino acid combinations with 6 distinct patterns of residues identified in the 11 patients who 
received DAA treatment (Table 5). Position 30 encoded an arginine residue which was invariant while 
position 31 encoded predominantly leucine with methionine present at a lower frequency. The highest 
variability was observed at position 28 with methionine found at highest frequency but four other amino 
acids were also encoded at this position (Table 5).  
DISCUSSION 
Our study had two major objectives; firstly, to analyse DAA treatment outcomes for individuals originating 
from countries across Africa, and secondly, to determine the HCV sequences circulating in the cohort. Given 
the sparsity of viral sequences at RAV positions and real-world outcomes of DAA therapy from African 



















The cohort totalled 319 individuals, originating from 32 African countries. This gives a broad geographical 
spread with larger groups coming from Egypt (Northern Africa), Nigeria (Western Africa), DRC/Republic of 
Congo (Central Africa), Somalia (Eastern Africa) and South Africa (Southern Africa). For most individuals, HCV 
infection was likely acquired in their country of origin given their more advanced stage of liver disease (Table 
1 and Supplementary Table 2) and the diversity of genotypes and subtypes represented in our analysis 
(Supplementary Tables 3, 4 and 6), as reported previously for African individuals [22-25, 28]. In addition, 
some individuals reported likely transmission in their country of origin (Supplementary Table 1). We cannot 
exclude the possibility that a proportion of infections occurred in the UK or in countries from which 
individuals did not originate. In the UK, HCV is predominantly found in People Who Inject Drugs (PWID) and 
the genotypes observed are almost exclusively gt1 (53%) and gt3 (41%, Supplementary Table 6). By contrast, 
African individuals had much lower occurrence of gt3 infection (8%) but far higher prevalence of gt4 
infection (47% compared to 0.5% in the UK PWID population; Supplementary Table 6). Moreover, the 
subtypes identified in the UK PWID population are typically gt1a, gt1b and gt3a (data not shown) but there is 
greater diversity of gt1 subtypes in the African group (Supplementary Tables 3 and 4) and there were no 
cases of gt3h in the UK PWID cohort. We did attempt to distinguish gt1a, gt1b and gt3a strains in African 
individuals compared to UK-based infections but phylogenetic analysis did not discriminate between 
possible UK and African strains (data not shown). Thus, it is highly probable that for the African group, HCV 
infection occurred in their country of origin. Far larger studies would be required to determine whether the 
higher prevalence of liver disease was associated with any virological factors given the infrequency of many 
of the subtypes outside Africa.  
Almost half of the cohort were treated with nine different DAA regimens including NS3 protease+NS5A 
inhibitors, NS5A+NS5B inhibitors and drug combinations against all three viral targets. The most frequently 
prescribed DAA therapies were SOF-based regimens (104/162, 64%). SOF was occasionally used as mono-



















or DCV) or triple combination (VEL/VOX; Table 2). The overall SVR for SOF-based treatment was 79% 
(82/104). This relatively low SVR rate was primarily a consequence of relapse with SOF/LDV in gt1l- and gt4r-
infected patients (Table 2). These findings confirm previous reports from ourselves and others on the lower 
SVR rates achieved with SOF/LDV therapy for both of these subtypes [9-14]. By contrast, 8 out of 9 patients 
(89%) infected with either gt1l or gt4r achieved SVR following treatment with either NS3/NS5A combinations 
or triple SOF/VEL/VOX treatment.  
Aside from gt1l and gt4r, the SVR for other gt1 and gt4 subtypes was 97%. This includes gt4d, another 
unusual subtype associated with treatment failure with OBV/PTV/r in a clinical trial [29]. There were four 
gt4d-infected patients in our study, all of whom achieved SVR with OBV/PTV/r (n=1) and SOF-based therapy 
(n=3). Thus, it is likely that there are few gt1 and gt4 subtypes, other than gt1l and gt4r, circulating in Africa 
that would not give high SVR rates for the various DAA therapies. Nonetheless, exceptions could arise such 
as the unassigned gt1 strain from a Nigerian patient who had a T28+S30+N93 amino acid combination in 
NS5A and was a responder-relapser to GRZ/ELB treatment (Patient 2 in Table 4). Moreover, the gt1a-
infected case, who was classified as a non-responder to GLE/PIB, had a natural M31 RAV in NS5A that 
appears infrequently in gt1a sequences but could arise more frequently in certain LMIC populations that 
have not been extensively analysed. Thus, continued survey of viral sequences in Africa and outcomes from 
therapy would be beneficial. 
13 patients in our cohort who were not successfully cured by initial DAA therapy received retreatment with 9 
achieving SVR. Aside from one individual who relapsed on retreatment, the more potent DAA combinations 
containing GLE/PIB and SOF/VEL/VOX achieved cure in 6 patients. SOF/VEL/VOX retreatment was 
unsuccessful in one individual with gt4r (Table 4) who had received previous unsuccessful SOF/LDV therapy. 
The reason for retreatment failure with SOF/VEL/VOX is not known since there were no serial samples 
available following SOF/LDV treatment. In addition, the patient did not have underlying severe liver disease. 



















explain lack of efficacy for VOX. It is possible that initial SOF treatment could have led to emergence of a 
S282T RAS in NS5B, which would yield high levels of resistance. From previous reports, S282T appears to 
emerge at higher frequency with gt4r than other HCV genotypes and subtypes [10, 13]. This RAS did emerge 
transiently in one patient in our study (Pt 9 in Table 4) following initial SOF/LDV treatment. We also found a 
V321I variant [12] in the NS5B sequences of 6 gt4r-infected patients who received SOF treatment; 3 patients 
achieved SVR while the remainder relapsed from therapy. Notably in the French study that documented 
successful retreatment outcomes in 7 patients infected with gt4r, again GLE/PIB and SOF/VEL/VOX were 
used in most retreatment regimens [13]. Overall, studies from our group and others agree that SOF/LDV 
therapy is sub-optimal and should not be recommended in regions with potentially significant prevalence of 
gt1l and gt4r infection. This recommendation is reinforced by a recent report using subgenomic replicons 
containing gt1l and gt4r NS5A sequences, which shows variants at positions 30 and 31 identified here 
increase resistance to LDV [30]. It is worth noting that African [14], UK [9, 10] and French studies [11-13] 
have now highlighted difficulties with treating patients of African origin infected with these subtypes using 
SOF/LDV therapy. Therefore, treating this patient group with a SOF/LDV combination in high income settings 
should be avoided unless robust HCV genotype/subtype assays are available. In resource limited settings 
where there is considerable diversity of HCV genotypes and subtypes that could include gt1l and gt4r, more 
potent pangenotypic DAA combinations should prove effective as either initial or rescue therapy thereby 
obviating the need for sophisticated assays for viral genotyping and subtyping. During the review of this 
manuscript, the most recent EASL guidelines excluded SOF/LDV as recommended therapy but do highlight 
the need for additional treatment outcome data for unusual HCV subtypes such as gt1l and gt4r with more 
potent DAA combinations [31]. 
In conclusion, our study describes HCV subtypes and viral sequences circulating in countries for which there 
are very limited data, and complements our recent report describing gt4 subtypes in Uganda and the 



















subtype across large geographical regions in Africa. Indeed, excluding Egypt where gt4a dominates [26, 32], 
gt4r is the most prevalent gt4 subtype in our study and therefore may be highly prevalent in certain African 
countries. Moreover, the extent of gt1l infection in Nigeria and other unassigned gt1 strains has not been 
fully evaluated. As highlighted in EASL guidelines, it would be prudent to continue to record outcome data to 
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Fig. 1. (A) Distribution of HCV genotypes from individuals originating from Northern, Western, Central, 
Eastern and Southern Africa. (B) Numbers of HCV genotypes and subtypes identified in individuals 






















Table 1. Demographics of HCV-infected individuals originating from Africa (n=319). 
 Gender (n=319) 
     









     
 Cirrhosis (n=131)a 
 
 Cirrhosis, no 
decompensation 
Decompensated HCC Decompensated 
+ HCC 











    












































a Stratification of HCV-infected cases with cirrhosis by disease type. 






















Table 2. DAA-only regimens and outcomes for individuals originating from Africa. 
 
  Rx outcomes (n=162) 





































2 0 0 0 
SOF/DCV or LDV 3 
3 
(100%)



































Table 3. SVR rates by HCV genotype and DAA regimen for patients with NGS data. 
 
 SVR (%) 
HCV 
genotype 




































































































Table 4. Characteristics of patients with unsuccessful DAA treatment episodes and outcomes of retreatment. 
 Liver Disease DAA Treatment Episodes and Outcomes 




Cirrhosis Decomp HCC Rx1 Outcome Rx2 Outcome 
1 gt1a Yes No No GLE/PIB NR No  
2 gt1- No No No GRZ/ELB/RBV RR No  
3 gt1l Yes No No SOF/LDV/RBV RR No  
4 gt1l Yes Yes Yes SOF/LDV/RBV RR SOF/LDV/RBV RR 
5 gt1l Yes Yes Yes SOF/DCV RR SOF/DCV RR 
6 gt3h Yes No No SOF/VEL/RBV RR No  
7 gt4a Yes No No SOF/LDV RR No  
8 gt4r Yes Yes Yes SOF/LDV/RBV RR No  
9 gt4r Yes Yes No SOF/LDV/RBV NR SOF/LDV/RBV RR 
10 gt4r No No No SOF/LDV RR SOF/VEL/VOX RR 
Patients who did achieve SVR on retreatment 
11 gt1a No No No SOF/LDV RR SOF/VEL/VOX SVR 
12 gt1b No No No SOF/RBV RR SOF/VEL/VOX SVR 
13 gt1c No No No SOF/LDV/RBV RR Clinical triala SVR 
14 gt1l Yes Yes Yes SOF/LDV/RBVb RR GLE/PIB SVR 
15 gt3a Yes Yes No SOF/LDV/RBV RR SOF/LDV/RBV SVR 
16 gt3a Yes Yes Yes SOF/LDV/RBV RR SOF/LDV/RBV SVR 
17 gt4a Yes No No OBV/PTV/r RR GLE/PIB SVR 
18 gt4o Yes No No SOF/VEL NR GLE/PIB SVR 
19 gt4r No No No SOF/LDV RR SOF/VEL/VOX SVR 
a DAA treatment used in clinical trial was not known. 



















Table 5. NS5A sequences at sites associated with DAA resistance and outcomes of DAA treatment regimens 
(Rx) for individuals infected with either gt1l or gt4r. 
 
NS5A Position Frequency NS3/NS5A Rx NS5A/NS5B Rx 
NS3/NS5A/ 
NS5B Rx 
28 30 31  NRx NSVR NRx NSVR NRx NSVR 
gt1l n=6 1 1 7 0 2 2 
M Q M n=3 0 0 3 0 1 1 
M R M n=3 1 1 4 0 1 1 
gt4r n=12 2 2 9 4 4 3 
M R L n=6 1 1 4 2 2 2 
M R M n=1 0 0 2 0 0 0 
V R L n=2 0 0 2 1 1 0 
F R L n=1 0 0 1 1 0 0 
I R L n=1 0 0 0 0 1 1 
T R L n=1 1 1 0 0 0 0 
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